Skip to main content

TG Therapeutics, Inc.

corporate_fare Company Profile

TG Therapeutics, Inc.

TGTX·NASDAQ·Life Sciences·CIK 0001001316

TG Therapeutics is a fully integrated, commercial-stage biotechnology company that acquires, develops, and sells new treatments for B-cell diseases. The company has a research pipeline and has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BRIUMVI has also been approved by several regulatory agencies outside the U.S. for adult RMS patients with active disease, defined by clinical or imaging features. The company also assesses complementary products, technologies, and companies for in-licensing, partnerships, acquisitions, and investment. In December 2022, BRIUMVI received FDA approval based on data from the ULTIMATE I & II Phase 3 trials, which showed it was superior to teriflunomide in significantly reducing the annualized relapse rate (ARR), the number of T1 Gd-enhancing lesions, and the number of new or enlarging T2 lesions. These trial results were published in August 2022. TG Therapeutics commercially launched BRIUMVI in the U.S. in January 2023. In August 2023, the company entered into a commercialization agreement with Neuraxpharm Pharmaceuticals, S.L. BRIUMVI is an anti-CD20 monoclonal antibody administered to adults with RMS via a one-hour infusion every 24 weeks after the initial dose.

TG Therapeutics, Inc. (NASDAQ:TGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for TGTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for TGTX spans 10-Q, 8-K, DEF 14A.

Recent high-impact activity:

  • ENHANCE Win: Single 600mg BRIUMVI Infusion Matches Two-Dose Regimen
  • TG Therapeutics Q3 2026: Revenue $259.9M, Net Income $55.5M, $556.7M Cash
  • TG Therapeutics Lifts 2026 Revenue Guidance to ~$1B as BRIUMVI Grows 52%
  • TG Therapeutics Posts 35c Q3 EPS as BRIUMVI Momentum Builds
  • Azer-Cel Shows 89% Stable or Improved Disability Scores in Progressive MS Phase 1

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$616.29M
Net Income
$447.18M
Diluted EPS
$2.77
Op. Cash Flow
-$24.77M
Free Cash Flow
-$24.99M
Gross Profit
$515.57M
Operating Income
$123.32M
Cash & Equivalents
$79.15M
Total Debt
$245.65M
Debt / Equity
0.38×
Net Margin
72.6%
Shares Outstanding
155.31M sh
Source: 10-K · filed 2026-02-27 · accession 0001437749-26-006133

Short Interest & Short Volume

18.89 days to cover

FINRA reported short interest of 28,765,675 shares in TGTX as of the October 30, 2026 settlement, a 2.8% decrease from the prior period — about 18.9 days to cover at its recent average daily volume. On November 20, 2026, 50.4% of TGTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)28,765,675 shares as of October 30, 2026
Change vs prior period▼ 2.8%
Days to cover18.89 at avg daily volume of 1,522,463
Daily short volume (FINRA facilities)50.4% of 720,837 shares on November 20, 2026
5-day average short volume46.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with T →
$63.21 -0.21% today
52-week range · as of 2026-11-09 $26.76 – $63.6
Market cap
$9.57B
Volume
2.1M (1.1× avg)
3-mo avg 1.9M
Live data · 2026-11-21 06:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TGTX - Latest Insights

TGTX
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $63.54
Real-time Price: $63.21 info
Change: -$0.3272 (-0.51%) info
Market Cap: $9.574B info
TGTX
Nov 09, 2026, 4:33 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $63.55
Real-time Price: $63.21 info
Change: -$0.340 (-0.54%) info
Market Cap: $9.574B info
TGTX
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.00
Real-time Price: $63.21 info
Change: +$0.210 (+0.33%) info
Market Cap: $9.574B info
TGTX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.11
Real-time Price: $63.21 info
Change: +$5.10 (+9%) info
Market Cap: $9.574B info
TGTX
Oct 23, 2026, 11:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $52.44
Real-time Price: $63.21 info
Change: +$10.77 (+21%) info
Market Cap: $9.574B info
TGTX
Aug 05, 2026, 5:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $50.48
Real-time Price: $63.21 info
Change: +$12.73 (+25%) info
Market Cap: $9.574B info
TGTX
Aug 03, 2026, 9:22 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $51.30
Real-time Price: $63.21 info
Change: +$11.91 (+23%) info
Market Cap: $9.574B info
TGTX
Aug 03, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $50.77
Real-time Price: $63.21 info
Change: +$12.44 (+25%) info
Market Cap: $9.574B info
TGTX
Jun 12, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $49.40
Real-time Price: $63.21 info
Change: +$13.81 (+28%) info
Market Cap: $9.574B info
TGTX
Jun 09, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $42.00
Real-time Price: $63.21 info
Change: +$21.21 (+51%) info
Market Cap: $9.574B info
TGTX
Jun 03, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.65
Real-time Price: $63.21 info
Change: +$26.56 (+72%) info
Market Cap: $9.574B info
TGTX
Jun 03, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $36.95
Real-time Price: $63.21 info
Change: +$26.26 (+71%) info
Market Cap: $9.574B info
TGTX
May 27, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $39.20
Real-time Price: $63.21 info
Change: +$24.01 (+61%) info
Market Cap: $9.574B info
TGTX
May 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $41.08
Real-time Price: $63.21 info
Change: +$22.13 (+54%) info
Market Cap: $9.574B info
TGTX
May 06, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $42.00
Real-time Price: $63.21 info
Change: +$21.21 (+51%) info
Market Cap: $9.574B info
TGTX
May 06, 2026, 7:25 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.18
Real-time Price: $63.21 info
Change: +$28.03 (+80%) info
Market Cap: $9.574B info
TGTX
May 06, 2026, 7:09 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.50
Real-time Price: $63.21 info
Change: +$26.71 (+73%) info
Market Cap: $9.574B info
TGTX
Apr 30, 2026, 4:31 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $33.21
Real-time Price: $63.21 info
Change: +$30.00 (+90%) info
Market Cap: $9.574B info
TGTX
Apr 15, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.27
Real-time Price: $63.21 info
Change: +$28.94 (+84%) info
Market Cap: $9.574B info
TGTX
Mar 20, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.07
Real-time Price: $63.21 info
Change: +$33.14 (+110%) info
Market Cap: $9.574B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets